Improved mood states with lamotrigine in patients with epilepsy
Improved mood states with lamotrigine in patients with epilepsy
复制标题
DOI：
10.1016/j.yebeh.2004.07.005
复制
发表时间：
2004-10-01
影响因子：
2.6
通讯作者：
Kustra, RP
中科院分区：
文献类型：
--
作者：
Cramer, JA;Hammer, AE;Kustra, RP
拉莫三嗪（LTG）与其他抗癫痫药物（AEDs）联合应用进行连续治疗研究。除了癫痫控制和不良反应外，还评估了患者情绪状态和生活质量的变化。在基线（N = 196）、添加LTG作为后续治疗后（N = 155）和停用LTG单药治疗后（N = 51），使用情绪状态量表（POMS）和31项癫痫生活质量量表（QOLIE-31）。POMS分数与QOLIE-31情绪幸福子量表（一种已知的情绪测量方法）高度相关。在连续治疗期结束时，所有POMS分量表均显著改善（均P < 0.0001）。在完成转换为单药治疗的患者中，POMS评分仍显著优于基线（均P < 0.003）。确定POMS评分的最小临床重要变化。这些数据表明，LTG改善情绪状态的临床重要程度，即使在其他AED的存在。这种改善可能不是协同作用，而是仅归因于LTG，因为它在停用其他AED后保持稳定。(C)2004年爱思唯尔公司All rights reserved.
Lamotrigine (LTG) was added to other antiepileptic drugs (AEDs) in a study of adjunctive therapy. In addition to seizure control and adverse effects, patients were evaluated for changes in mood states and quality of life. The Profile of Mood States (POMS) and 31-item Quality of Life in Epilepsy (QOLIE-31) instruments were administered at baseline (N = 196), after addition of LTG as adjunctive treatment (N = 155), and after withdrawal of other drugs to LTG monotherapy (N = 51). POMS scores correlated highly with the QOLIE-31 Emotional Well-Being subscale, a known measure of mood. All POMS subscales were significantly improved (all P < 0.0001) at the end of the adjunctive therapy phase. POMS scores remained significantly better than baseline among patients completing the conversion to monotherapy (all P < 0.003). Minimal clinically important changes were determined for POMS scores. These data indicate that LTG improves mood states to a clinically important degree, even in the presence of other AEDs. The improvement likely was not a synergy but attributable only to LTG because it remained stable after withdrawal of the other AEDs. (C) 2004 Elsevier Inc. All rights reserved.